# Carotid Plaque and 3D Ultrasound: A Smarter Way to Predict and Prevent Heart Attacks and Strokes This review article explains why measuring carotid plaque burden—the actual amount of plaque buildup in the neck arteries—is far more powerful for predicting heart attacks and strokes than the traditional measurement called carotid intima-media thickness (IMT). The authors, Dr. J. David Spence and Dr. Grace Parraga from Western University in Canada, present evidence that tracking how plaque area and plaque volume change over time strongly predicts cardiovascular events, while IMT progression does not. They also describe a practical clinical strategy called "treating arteries instead of treating risk factors" that markedly reduces risk in patients with asymptomatic carotid stenosis. This patient-friendly article translates their findings into clear, actionable information. # Carotid Plaque and 3D Ultrasound: A Smarter Way to Predict and Prevent Heart Attacks and Strokes ## Table of Contents - Key Points - Why This Research Matters: The Silent Danger of Carotid Plaque - The Problem with Traditional Measurements: IMT vs. Plaque Burden - How the Research Was Conducted: Measuring Plaque with Ultrasound - Key Findings: What Two Decades of Research Shows - Beyond the Clinic: Genetic Research and New Therapies - Clinical Implications: "Treating Arteries Instead of Treating Risk Factors" - What This Means for You: Recommendations for Patients - Limitations of This Research - Frequently Asked Questions - Source Information ## Key Points - Carotid total plaque area predicts cardiovascular risk more strongly than carotid intima-media thickness (IMT). - IMT progression does not predict heart attacks or strokes, but progression of total plaque area and volume does. - 3D ultrasound measures full plaque volume without radiation and gives more consistent results than standard 2D ultrasound. - A strategy called 'treating arteries' uses repeat plaque imaging to adjust therapy, markedly reducing risk in asymptomatic carotid stenosis. - Plaque burden measurement speeds up genetic research and early-phase drug trials by serving as a sensitive surrogate endpoint. ## Why This Research Matters: The Silent Danger of Carotid Plaque Your carotid arteries are the two large blood vessels on each side of your neck that carry oxygen-rich blood from your heart to your brain. When cholesterol, fat, and other substances build up inside these arteries, they form a waxy deposit called plaque. This process is known as **atherosclerosis**, and it is the leading cause of heart attacks and strokes worldwide. Here is the alarming part: plaque buildup often happens silently. Many people have significant carotid plaque and feel perfectly fine. They may not experience any warning signs until a piece of plaque breaks loose, travels to the brain, and causes a stroke, or until the artery becomes so narrowed that blood flow is severely reduced. Detecting and measuring this plaque early is therefore critical. This review article, published in *Neuroimaging Clinics of North America* in February 2016, examines how modern three-dimensional (3D) ultrasound technology can measure plaque more accurately than older methods—and why that accuracy directly translates into better prediction of who is at risk for a heart attack or stroke. The key message from the authors is simple but profound: **what you measure matters**. The traditional way of measuring artery wall thickness has important limitations. Measuring the actual plaque burden—the total area and volume of plaque—is a far stronger predictor of cardiovascular danger. ## The Problem with Traditional Measurements: IMT vs. Plaque Burden For decades, doctors have used a measurement called **carotid intima-media thickness (IMT)** to assess cardiovascular risk. This is a measurement of the thickness of the two inner layers of the carotid artery wall—the intima and the media—obtained using standard two-dimensional (2D) ultrasound. Think of the artery wall like a water pipe. The IMT measures the thickness of the pipe's inner lining. It is a useful marker of general wear and tear. However, it does not directly measure the actual blockage—the plaque itself. The authors of this review make a critical distinction: - **IMT** measures the thickness of the artery wall's inner layers across a small segment. - **Plaque burden** measures the actual amount of atherosclerotic plaque—the area of plaque visible in a 2D view, or the total volume of plaque in three dimensions. This difference is not just academic. The research reviewed in this article shows that these two measurements behave very differently when it comes to predicting patient outcomes. In fact, the authors state plainly that "carotid total plaque area is a stronger predictor of cardiovascular risk than IMT." Even more striking, the two measurements diverge dramatically when tracked over time. The progression of IMT—meaning the rate at which the wall thickness increases over months or years—does **not** predict cardiovascular events. A patient's IMT can get worse, yet that worsening tells doctors little about whether that patient will actually have a heart attack or stroke. This finding surprised many clinicians. For years, IMT was considered a reliable surrogate marker in research trials. The authors of this review argue that this assumption was flawed. By contrast, the progression of total plaque area and total plaque volume strongly predicts cardiovascular events. When a patient's plaque is growing, their risk of a heart attack or stroke rises substantially. When plaque is stable or shrinking, their risk falls. This makes plaque burden measurement a much more clinically useful tool. ## How the Research Was Conducted: Measuring Plaque with Ultrasound This article is a review, which means the authors did not conduct a single new experiment. Instead, they systematically examined and synthesized the findings of many prior studies and clinical trials on carotid plaque measurement. Their goal was to evaluate the evidence for using plaque burden measurement in clinical practice, genetic research, and therapy assessment. The central imaging technology discussed is **three-dimensional ultrasound (3D ultrasound)**. Traditional carotid ultrasound produces flat, two-dimensional images of the artery. A technician moves a probe across the neck, capturing a series of 2D slices. Interpreting these images requires skill, and measurements can vary from one technician to another. Three-dimensional ultrasound takes this a step further. A specialized probe captures many closely spaced 2D images in a single sweep. Computer software then reconstructs these images into a 3D volume, much like a CT scan or MRI does. This provides several major advantages: - **Complete visualization:** The entire plaque can be seen in three dimensions, including its length, width, and depth, rather than just a single slice. - **Accurate volume measurement:** Because the full shape of the plaque is captured, the software can calculate total plaque volume, not just area. - **Better reproducibility:** Measurements taken on different days or by different technicians are more consistent, which is essential for tracking changes over time. - **No radiation:** Unlike CT scans, ultrasound uses no ionizing radiation, making it safe for repeated imaging. For research purposes, the authors emphasize two key endpoints: **total plaque area** (the cross-sectional area of all plaque visible in the carotid arteries) and **total plaque volume** (the three-dimensional volume of all plaque). Both can be measured longitudinally—meaning at multiple visits over time—to track whether plaque is growing, stable, or regressing. The review also touches on how these measurements have been validated against other imaging methods, such as magnetic resonance imaging (MRI), and how they have been applied in large patient cohorts and drug trials. ## Key Findings: What Two Decades of Research Shows The authors present several core findings that have important implications for cardiovascular medicine. ### Finding 1: Plaque Area Outperforms IMT as a Predictor of Risk In head-to-head comparisons, carotid total plaque area proved to be a stronger predictor of cardiovascular risk than IMT. This means that measuring how much plaque a patient actually has tells doctors more about that patient's likelihood of experiencing a heart attack, stroke, or other cardiovascular event than measuring the thickness of the artery wall. ### Finding 2: IMT Progression Is Not Predictive, but Plaque Progression Is This is perhaps the most important finding in the review. When researchers followed patients over time, they found: - The rate of IMT progression did **not** predict which patients would have cardiovascular events. - The rate of total plaque area progression and total plaque volume progression **strongly** predicted cardiovascular events. In plain language: watching whether plaque is getting bigger is far more informative than watching whether the artery wall is getting thicker. This finding has reshaped how researchers design clinical trials and how some clinicians monitor their patients. ### Finding 3: Measuring Plaque Burden Is Useful for Genetic Research Because plaque burden is a precise, quantitative measurement, it is well-suited for genetic studies. Researchers can compare plaque burden across thousands of individuals to identify genes that influence susceptibility to atherosclerosis. The ability to track plaque progression over time also allows researchers to study how genetic variations affect the rate of disease progression, not just its presence or absence. ### Finding 4: Plaque Measurement Accelerates Evaluation of New Therapies Historically, drug trials for atherosclerosis relied on waiting for cardiovascular events—heart attacks, strokes, or deaths—to occur. These trials require thousands of patients followed for many years, making them slow and expensive. Using plaque burden as a surrogate endpoint changes this calculus. If a new medication causes measurable plaque regression—or slows plaque progression—within a year or two, researchers can gain confidence in its effectiveness much earlier. This accelerates the development of new therapies for atherosclerosis and makes clinical trials more efficient. ### Finding 5: "Treating Arteries" Markedly Reduces Risk in Asymptomatic Patients The authors describe a management strategy they call **"treating arteries instead of treating risk factors."** This concept represents a philosophical shift in preventive medicine. Instead of simply treating individual risk factor numbers—like lowering LDL cholesterol to a target level or reducing blood pressure to a specific reading—the goal becomes stabilizing or regressing the actual disease: the plaque in the arteries. When this strategy was applied to patients with **asymptomatic carotid stenosis** (plaque narrowing the carotid artery without causing symptoms like a transient ischemic attack or stroke), the results were striking: the risk was **markedly reduced**. The idea is that blood tests and risk factor calculators tell you a patient's statistical risk. But measuring the arteries themselves tells you what is actually happening in that specific patient. If plaque is growing despite treatment, the treatment is not working well enough, regardless of what the cholesterol numbers say. If plaque is regressing, the treatment is working, and the patient can be reassured. ## Beyond the Clinic: Genetic Research and New Therapies The value of plaque burden measurement extends beyond routine patient care. The authors highlight two major research applications. First, in **genetic research**, the precision of 3D plaque volume measurements makes them excellent phenotypes—measurable traits—for genome-wide association studies. By linking genetic variations to differences in plaque burden and plaque progression, researchers can identify new biological pathways involved in atherosclerosis. These discoveries can, in turn, reveal new drug targets. Second, in **therapeutic evaluation**, plaque measurement provides a sensitive and reproducible way to assess whether an investigational drug is working. This is especially valuable for early-phase trials, where the goal is to determine whether a drug has a biological effect before committing to a massive, multi-year outcomes trial. The authors note that validated methods for measuring plaque burden are now well established, making these applications feasible in real-world research settings. ## Clinical Implications: "Treating Arteries Instead of Treating Risk Factors" Perhaps the most actionable takeaway for patients is the treatment philosophy championed by Dr. Spence, who has spent decades studying stroke prevention at the Stroke Prevention and Atherosclerosis Research Centre in London, Ontario. The traditional medical approach to preventing heart attack and stroke focuses on risk factors: 1. Measure LDL cholesterol. If too high, prescribe a statin. 1. Measure blood pressure. If too high, prescribe an antihypertensive. 1. Measure blood sugar. If elevated, address diabetes. 1. Encourage smoking cessation, exercise, and dietary changes. This approach works well at a population level. But it has a blind spot: it treats numbers, not the underlying disease process. The "treating arteries" approach uses imaging to personalize therapy. Here is how it works: 1. **Measure plaque burden** with ultrasound at the initial visit. 1. **Aggressively treat risk factors**—using lifestyle changes and medications—with the specific goal of halting plaque growth. 1. **Repeat the ultrasound** after one year to measure the new plaque burden. 1. **Compare the two scans.** If plaque has stabilized or regressed, the treatment is working. If plaque has progressed, treatment is intensified—perhaps with a higher statin dose, additional medications, or more aggressive lifestyle intervention. This creates a feedback loop. The artery itself becomes the patient's own "lab test." The therapy is adjusted based on the actual response of the disease, rather than on estimated risk. The authors report that when this strategy was applied to patients with asymptomatic carotid stenosis—patients who have significant plaque but have not yet experienced symptoms—the risk reduction was marked. This matters enormously because asymptomatic carotid stenosis is a major risk factor for future stroke. Identifying these patients and treating them aggressively can prevent disabling or fatal events. ## What This Means for You: Recommendations for Patients Based on this review, here are practical steps patients can consider discussing with their healthcare providers: - **Ask about plaque imaging:** If you have risk factors for heart disease or stroke—such as high cholesterol, high blood pressure, diabetes, smoking history, or a family history of cardiovascular disease—ask your doctor whether a carotid ultrasound to measure plaque burden is appropriate for you. - **Know your plaque status, not just your cholesterol numbers:** Cholesterol numbers are important, but they do not tell you the full story. Measuring actual plaque can provide a more direct assessment of your vascular health. - **If you have known plaque, ask about follow-up imaging:** The research shows that tracking whether plaque is growing over time is highly predictive of risk. One year after starting or intensifying therapy, a repeat ultrasound can tell you whether the treatment is working. - **Understand that "treating arteries" may mean more aggressive therapy:** If your plaque is progressing, your doctor may recommend intensifying your treatment—this could mean a higher-dose statin, additional cholesterol-lowering medications, stricter blood pressure control, or more comprehensive lifestyle changes. - **Do not be afraid of ultrasound:** Carotid ultrasound is safe, painless, non-invasive, and involves no radiation. It can be repeated safely over many years. - **Focus on plaque stability as a goal:** The goal of therapy is to stop plaque from growing, and ideally to shrink it. Even achieving stability—no further growth—is a meaningful victory that reduces risk. ## Limitations of This Research It is important to understand what this review does and does not claim. The article is a review of existing research, not a single new clinical trial. As with all scientific work, there are limitations to consider. **First**, 3D ultrasound requires specialized equipment and training. Not all clinics have access to this technology. Standard 2D ultrasound measurements of plaque area are also useful, but 3D volume measurement provides additional precision. **Second**, the review focuses primarily on carotid plaque. Atherosclerosis is a systemic disease, and plaque also develops in the coronary arteries of the heart, the aorta, and peripheral arteries. Carotid plaque burden is a strong marker of overall risk, but it does not capture every aspect of the disease. **Third**, while the "treating arteries" strategy has been shown to markedly reduce risk, the optimal treatment protocols—exact drug regimens, target levels, and follow-up intervals—continue to evolve. Patients should work with their healthcare team to develop an individualized plan. **Fourth**, the abstract and review describe associations and predictive relationships. While plaque progression strongly predicts events, no measurement is perfect. Some patients with stable plaque still have events, and some with progressing plaque do not. **Fifth**, the review was published in 2016. While its core findings remain valid and influential, the field of vascular imaging continues to advance. Newer techniques, including artificial intelligence-assisted image analysis, have since built upon this foundation. ## Frequently Asked Questions ### What is carotid plaque and why is it dangerous? Carotid plaque is a waxy buildup of cholesterol, fat, and other substances inside the two large neck arteries that supply blood to the brain. Many people have significant plaque without feeling any symptoms. The danger is that a piece can break loose, travel to the brain, and cause a stroke, or severely narrow the artery and reduce blood flow. ### How is 3D ultrasound different from a traditional carotid ultrasound? Traditional ultrasound takes flat, two-dimensional slices of the artery, and measurements can vary between technicians. Three-dimensional ultrasound captures many closely spaced images in one sweep, then computer software reconstructs them into a 3D volume. This allows complete visualization of the plaque, accurate volume measurement, and better reproducibility when tracking changes over time. ### Why is measuring plaque burden better than measuring carotid intima-media thickness (IMT)? IMT measures the thickness of the artery wall's inner layers, like a water pipe's lining. Plaque burden measures the actual amount of atherosclerotic plaque in area or volume. Research shows carotid total plaque area is a stronger predictor of cardiovascular risk than IMT. Also, IMT progression does not predict heart attacks or strokes, while plaque progression strongly does. ### What does 'treating arteries instead of treating risk factors' mean? Instead of only treating cholesterol or blood pressure numbers, this strategy uses ultrasound to measure plaque burden at the start. After treating risk factors aggressively for about a year, another ultrasound compares the plaque. If plaque is stable or smaller, treatment works. If plaque has grown, therapy is intensified. The artery itself becomes the guide for therapy. ### What should I ask my doctor about measuring my carotid plaque? If you have risk factors like high cholesterol, high blood pressure, diabetes, smoking history, or a family history of heart disease, ask whether a carotid ultrasound to measure plaque burden is appropriate. Ask about your plaque status, not just your cholesterol numbers. If you already have plaque, ask about follow-up imaging one year after starting or intensifying therapy. ### Is carotid ultrasound safe for repeated imaging? Yes. Carotid ultrasound is safe, painless, non-invasive, and involves no radiation, unlike CT scans. It can be repeated safely over many years, which makes it very useful for monitoring whether plaque is growing, stable, or regressing over time. This ability to track plaque progression is what makes it so helpful for guiding treatment. ### What does it mean if my carotid plaque is growing despite treatment? In the research reviewed, when total plaque area or volume increases over time, the risk of a heart attack or stroke rises substantially. If your plaque is progressing, your doctor may recommend intensifying your therapy—for example, a higher-dose statin, additional cholesterol-lowering medications, stricter blood pressure control, or more comprehensive lifestyle changes. Plaque stability is already a meaningful victory. ### Should I get a second opinion on my carotid ultrasound plaque measurement before deciding on treatment? A second opinion can be valuable if your doctor recommends treatment based on carotid intima-media thickness (IMT) rather than plaque burden. Research shows that measuring total plaque area or volume with 3D ultrasound predicts heart attack and stroke risk more strongly than IMT, and that tracking plaque progression over time is more informative than IMT changes. If your treatment plan relies on IMT or if you are unsure whether your plaque is being monitored correctly, an independent review of your imaging and risk factors may help clarify whether your therapy should be adjusted. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information This patient-friendly article is based on the following peer-reviewed scientific publication: **Original Title:** Three-Dimensional Ultrasound of Carotid Plaque **Authors:** J. David Spence, MD, FRCPC, FAHA; Grace Parraga, PhD **Journal:** Neuroimaging Clinics of North America, February 2016, Volume 26, Issue 1, pages 69–80 **DOI:** 10.1016/j.nic.2015.09.006 **PMID:** 26610661 **Affiliations:** Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada; Imaging Research Laboratories, Department of Medical Biophysics, Robarts Research Institute, Western University, London, Ontario, Canada. This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace professional medical advice. Always consult your physician about your individual health situation. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/carotid-plaque-and-3d-ultrasound-a-smarter-way-to-predict-and-prevent-heart-attacks-and-strokes